StockData
Structure Therapeutics Inc. logo

Structure Therapeutics Inc. (GPCR) shareholders

GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$18.17−0.40 (-2.15%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
31.6%
68M of 214M shares
Institutional holders
192
29 new, 31 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
FMR LLC
Joint filing with Abigail P. Johnson (15.00%)
32,089,43415.00%13G (passive) amendmentSep 30, 2026
Abigail P. Johnson
Joint filing with FMR LLC (13.20%)
28,197,36913.20%13G (passive) amendmentJun 30, 2026
Wellington Investment Advisors Holdings LLP
Joint filing with Wellington Management Group LLP (10.10%), Wellington Group Holdings LLP (10.10%) and 1 more
21,365,95210.10%13G (passive) amendmentDec 31, 2025
Wellington Group Holdings LLP
Joint filing with Wellington Management Group LLP (11.90%), Wellington Investment Advisors Holdings LLP (11.90%) and 1 more
20,631,49811.90%13G (passive) amendmentOct 31, 2025
Wellington Management Group LLP
Joint filing with Wellington Group Holdings LLP (9.90%), Wellington Investment Advisors Holdings LLP (9.90%) and 1 more
17,067,5619.90%13G (passive) amendmentSep 30, 2025
Avoro Capital Advisors LLC
Joint filing with Aghazadeh Behzad (9.38%)
16,216,6659.38%13G (passive)Sep 30, 2025
Deep Track Biotechnology Master Fund, Ltd.
Joint filing with Deep Track Capital, LP (8.92%), David Kroin (8.92%)
15,401,7518.92%13G (passive) amendmentJun 30, 2025
Deep Track Capital, LP
Joint filing with Deep Track Biotechnology Master Fund, Ltd. (7.32%), David Kroin (7.32%)
12,647,4337.32%13G (passive) amendmentSep 30, 2025
David Kroin
Joint filing with Deep Track Capital, LP (5.95%), Deep Track Biotechnology Master Fund, Ltd. (5.95%)
12,335,3465.95%13G (passive) amendmentDec 31, 2025
Lampert Mark N
Joint filing with Bvf Partners L P/Il (5.60%), Bvf Inc/Il (5.60%) and 1 more
9,611,7515.60%13G (passive)Aug 11, 2025
Janus Henderson Group PLC4,448,8267.70%13G (passive) amendmentSep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GPCRValueChange% of portfolio
FMR LLC7,810,3063.65%$419.18M−593,1430.02%
Wellington Management Group Llp7,379,4333.45%$396.05M+119,1460.07%
Avoro Capital Advisors LLC6,555,5553.06%$351.84M–3.16%
Jupiter Topco LLC5,204,2122.43%$279.34MNew0.11%
Deep Track Capital, LP4,740,0722.22%$254.40M+460,2243.70%
Bvf Inc/Il3,366,8231.57%$180.70M−92,5354.62%
Morgan Stanley2,806,6401.31%$150.63M+501,1830.01%
Orbimed Advisors LLC2,209,4001.03%$118.58M+733,9972.20%
Principal Financial Group Inc1,752,7530.82%$94.07M−1,0110.05%
American Century Companies Inc1,682,1790.79%$90.28M+244,1480.04%
Rtw Investments, LP1,607,5070.75%$86.27MNew0.74%
Driehaus Capital Management LLC1,553,2190.73%$83.36M−24,1370.48%
Baker Bros. Advisors LP1,432,5290.67%$76.88M–0.39%
Casdin Capital, LLC1,175,0000.55%$63.06M–3.16%
Deerfield Management Company, L.P. (Series C)1,086,0000.51%$58.29M+318,0070.61%
Capitolis Liquid Global Markets LLC1,041,1000.49%$55.88M−110,2000.24%
Siren, L.L.C.872,9670.41%$46.85M−455,7310.95%
Price T Rowe Associates Inc /Md/845,5320.40%$45.38M−1,155,1640.00%
Pacific Heights Asset Management LLC800,0000.37%$42.94M+50,0001.36%
Rock Springs Capital Management LP640,3170.30%$34.37M+1001.68%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202619268M31.6%29 / 7651 / 3112M6M
Q1 202619667M31.3%40 / 7357 / 398M6M
Q4 202519766M30.8%71 / 5262 / 2720M11M
Q3 202515657M26.5%22 / 5749 / 3713M11M
Q2 202517255M25.6%38 / 6344 / 169M10M
Q1 202515056M26.2%23 / 4750 / 364M9M
Q4 202416461M28.4%29 / 6450 / 238M9M
Q3 202416062M28.8%28 / 6835 / 339M7M
Q2 202416660M28.2%61 / 6333 / 1323M7M
Q1 202411944M20.7%25 / 4535 / 269M8M
Q4 202312143M20.0%54 / 3625 / 1719M9M
Q3 20238433M15.3%42 / 296 / 617M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

141 funds held GPCR in Q2 2026, 4% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of GPCRValue% of fundAs of
Vanguard Health Care Fund3,278,2371.53%$157.49M0.41%Jul 31, 2026
Heritage Fund967,3530.45%$46.47M0.87%Jul 31, 2026
Fidelity Advisor Growth Opportunities Fund733,5000.34%$28.86M0.08%May 31, 2026
Global Emerging Markets Fund625,7510.29%$30.06M0.40%Jul 31, 2026
Janus Henderson Global Life Sciences Fund549,3530.26%$29.48M0.51%Jun 30, 2026
Select Biotechnology Portfolio542,0380.25%$21.32M0.40%May 31, 2026
Select Health Care Portfolio540,0000.25%$21.24M0.37%May 31, 2026
Fidelity Advisor Biotechnology Fund527,9000.25%$25.36M1.15%Jul 31, 2026
Janus Henderson Triton Fund467,1120.22%$25.07M0.42%Jun 30, 2026
Fidelity Stock Selector Small Cap Fund433,1000.20%$20.81M0.28%Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.419,4070.20%$22.51M0.19%Jun 30, 2026
Fidelity Small Cap Growth Fund414,3890.19%$19.91M0.23%Jul 31, 2026
iShares Biotechnology ETF414,2610.19%$22.23M0.24%Jun 30, 2026
Vanguard Explorer Fund405,6060.19%$19.49M0.09%Jul 31, 2026
Permanent Portfolio400,0000.19%$19.22M0.27%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Raymond C. StevensCHIEF EXECUTIVE OFFICER, Director2,956,1791.38%Mar 23, 2026
Crespo Blas CollCHIEF MEDICAL OFFICER258,2280.12%Sep 22, 2026
Xichen LinCHIEF SCIENTIFIC OFFICER228,9600.11%Sep 2, 2026
John Joseph BerriosChief Commercial Officer140,7660.07%Aug 7, 2026
Matthew LangCOO & GC184,6140.09%Apr 23, 2026
Jun YoonCHIEF FINANCIAL OFFICER2,956,2421.38%Mar 23, 2026
Yingli MaCHIEF TECHNOLOGY OFFICER139,9170.07%Mar 23, 2026
Ashley HallChief Development Officer155,1870.07%Mar 23, 2026
Eric DobmeierDirector––Jun 18, 2026
Angus C. RussellDirector––Jun 18, 2026
Ted W. LoveDirector––Jun 18, 2026
Daniel G. WelchDirector123,5080.06%Jun 18, 2026
Sharon TetlowDirector––Jun 18, 2026
Joanne WaldstreicherDirector––Jun 18, 2026
Llc Fmr10% owner261,7770.12%Jul 24, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Sep 21, 2026Conversion−12,024––258,228
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Sep 18, 2026Tax withholding−10,626$11.67$124.01K270,252
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Sep 1, 2026Conversion−17,817––228,960
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Sep 1, 2026Option exercise+17,817$0.34$6.06K246,777
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Aug 18, 2026Option exercise+11,817$0.34$4.02K240,777
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Aug 18, 2026Conversion−11,817––228,960
John Joseph Berrios
Chief Commercial Officer
Aug 6, 2026Award+140,766––140,766
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Aug 4, 2026Conversion−11,817––228,960
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Aug 4, 2026Option exercise+11,817$0.34$4.02K240,777
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Jul 14, 2026Conversion−23,634––228,960
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Jul 14, 2026Option exercise+23,634$0.34$8.04K252,594
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Jun 25, 2026Conversion−23,634––228,960
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Jun 25, 2026Option exercise+23,634$0.34$8.04K252,594
Matthew Lang
COO & GC
Apr 15, 2026Award+184,614––184,614
Yingli Ma
CHIEF TECHNOLOGY OFFICER
Mar 19, 2026Award+32,526––139,917
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Mar 19, 2026Award+43,368––228,960
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Mar 19, 2026Award+260,217––1,401,593
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Mar 19, 2026Award+75,897––280,878
Ashley Hall
Chief Development Officer
Mar 19, 2026Award+47,706––155,187
Jun Yoon
CHIEF FINANCIAL OFFICER
Mar 19, 2026Award+104,085––1,401,656
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Mar 3, 2026Tax withholding−53,454$20.99$1.12M1,141,376
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Mar 3, 2026Tax withholding−18,735$20.99$393.25K185,592
Jun Yoon
CHIEF FINANCIAL OFFICER
Mar 3, 2026Tax withholding−22,305$20.99$468.18K1,297,571
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Mar 3, 2026Tax withholding−11,826$20.99$248.23K204,981
Ashley Hall
Chief Development Officer
Mar 3, 2026Tax withholding−4,836$20.99$101.51K107,481
Yingli Ma
CHIEF TECHNOLOGY OFFICER
Mar 3, 2026Tax withholding−11,313$20.99$237.46K107,391
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Sep 18, 2025Tax withholding−8,106$7.74$62.74K216,807
Ashley Hall
Chief Development Officer
Sep 18, 2025Tax withholding−6,021$7.74$46.60K112,317
Yingli Ma
CHIEF TECHNOLOGY OFFICER
Jul 1, 2025Tax withholding−4,470$6.84$30.57K118,704
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Jul 1, 2025Tax withholding−12,846$6.84$87.87K204,327
Yingli Ma
CHIEF TECHNOLOGY OFFICER
Jul 1, 2025Award+24,459––123,174
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Jul 1, 2025Tax withholding−1,434$6.84$9.81K224,913
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Jul 1, 2025Award+7,992––226,347
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Jul 1, 2025Award+57,078––217,173
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Jul 1, 2025Award+89,697––1,210,880
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Jul 1, 2025Tax withholding−16,050$6.84$109.78K1,194,830
Jun Yoon
CHIEF FINANCIAL OFFICER
Jul 1, 2025Tax withholding−7,089$6.84$48.49K1,319,876
Jun Yoon
CHIEF FINANCIAL OFFICER
Jul 1, 2025Award+39,606––1,326,965
Ashley Hall
Chief Development Officer
Mar 15, 2025Award+51,048––118,338
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Mar 15, 2025Award+340,332––1,133,678
Yingli Ma
CHIEF TECHNOLOGY OFFICER
Mar 15, 2025Award+63,810––100,539
Crespo Blas Coll
Chief Medical Officer
Mar 15, 2025Award+116,988––219,588
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Mar 15, 2025Award+80,829––166,536
Jun Yoon
CHIEF FINANCIAL OFFICER
Mar 15, 2025Award+170,166––1,293,299
Yingli Ma
CHIEF TECHNOLOGY OFFICER
Mar 1, 2025Tax withholding−1,824$7.92$14.45K98,715
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Mar 1, 2025Tax withholding−1,233$7.92$9.77K218,355
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Mar 1, 2025Tax withholding−6,441$7.92$51.01K160,095
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Mar 1, 2025Tax withholding−12,495$7.92$98.96K1,121,183
Jun Yoon
CHIEF FINANCIAL OFFICER
Mar 1, 2025Tax withholding−5,940$7.92$47.04K1,287,359
Crespo Blas Coll
Chief Medical Officer
Sep 18, 2024Award+90,600––102,600
Ashley Hall
Chief Development Officer
Sep 18, 2024Award+67,290––67,290
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Jun 12, 2024Option exercise+99,999$0.39$39.00K743,345
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Jun 12, 2024Option exercise+50,001$0.48$24.00K793,346
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Jun 10, 2024Conversion−555,000––643,346
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Jun 3, 2024Conversion−106,200––85,707
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Jun 3, 2024Option exercise+106,200$0.34$36.11K191,907
Mark Allen Bach
CHIEF MEDICAL OFFICER
Mar 15, 2024Award+26,235––26,235
Raymond C. Stevens
CHIEF EXECUTIVE OFFICER, Director
Mar 15, 2024Award+134,682––1,198,346
Xichen Lin
CHIEF SCIENTIFIC OFFICER
Mar 15, 2024Award+85,707––85,707
Jun Yoon
CHIEF FINANCIAL OFFICER
Mar 15, 2024Award+59,469––1,123,133

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
6M shares short
Days to cover
6.5
At 1M shares a day
Change since last report
-17.1%
From 7M shares
Short volume, 20 days
38.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Structure Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,578 shares on Oct 1, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Crespo Blas Coll
Officer
Sep 21, 20264,008$140.28KSep 21, 2026Restricted Stock Units
Xichen Lin
Officer
Jun 25, 202635,512$1.71MJun 25, 2026Exercise of Stock Options
Raymond C. Stevens
Officer
Jun 10, 2024185,000$9.77MJun 10, 2024Founder Stock
Xichen Lin
Officer
Jun 3, 202459,000$2.02MJun 3, 2024Exercise of Stock Options

See a number that looks wrong?